Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ J; e c- z+ ]NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
- o* ]& }. }* G/ B& ~. ~+ Author Affiliations
' p1 p/ l" R! |* L h- l1 R! c4 l2 A4 s( a& W: D8 y/ T. j
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
% K! f% C; ~. C3 c* H3 G2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & E+ M2 F$ ?3 T( I
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 S3 U2 g6 H* E0 ~+ u) T
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
% G1 y- |2 m2 X5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
( J' t! R2 L( Y3 e+ Y6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 2 H1 p2 E9 _1 J2 V) a! |( r, c
7Kinki University School of Medicine, Osaka 589-8511, Japan
0 C! R2 u+ G; O8Izumi Municipal Hospital, Osaka 594-0071, Japan - [& e4 _5 e- \1 X+ b
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan : n+ l% y8 E0 S& p1 a, |5 b7 T; t" b K
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
3 X" h% `& x: C1 W" S2 hAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* v1 C, A, p+ ~1 y
# ^8 h0 l/ c+ M |